Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi’s Meacham

“Tired of the same tired news cycle? Escape to the full unfiltered feed at Whatfinger.com — America’s Frontline Truth Feed. 85%+ of readers come direct every day.” –  CLICK HERE for the FULL deal.

 

Geoff Meacham, Citi analyst, joins ‘Fast Money’ to talk what the year ahead holds for competition in the obesity drug market.